IOVANCE BIOTHERAPEUTICS Files 8-K

TL;DR

IOVA filed an 8-K on April 3rd, likely with financial updates. Keep an eye out.

AI Summary

On April 3, 2024, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific dollar amounts or new material events were detailed in the provided excerpt.

Why It Matters

This filing signifies an official update from IOVANCE BIOTHERAPEUTICS, INC. to the SEC, potentially containing material information for investors regarding financial statements or other significant corporate events.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational risks.

Key Players & Entities

• IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
• Lion Biotechnologies, Inc. (company) — Former Company Name
• Genesis Biopharma, Inc (company) — Former Company Name
• FREIGHT MANAGEMENT CORP (company) — Former Company Name

FAQ

Key Financial Figures

• $0.000041666 — h registered Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Marke
• $600,000 — e Company to pay to plaintiff's counsel $600,000 for certain legal fees and expenses. O

Filing Documents

• tm2410795d1_8k.htm (8-K) — 27KB
• tm2410795d1_ex99-1.htm (EX-99.1) — 29KB
• tm2410795d1_ex99-1img001.jpg (GRAPHIC) — 204KB
• tm2410795d1_ex99-1img002.jpg (GRAPHIC) — 297KB
• tm2410795d1_ex99-1img003.jpg (GRAPHIC) — 273KB
• tm2410795d1_ex99-1img004.jpg (GRAPHIC) — 252KB
• tm2410795d1_ex99-1img005.jpg (GRAPHIC) — 296KB
• tm2410795d1_ex99-1img006.jpg (GRAPHIC) — 288KB
• tm2410795d1_ex99-1img007.jpg (GRAPHIC) — 204KB
• tm2410795d1_ex99-1img008.jpg (GRAPHIC) — 144KB
• 0001104659-24-043158.txt ( ) — 2936KB
• iova-20240403.xsd (EX-101.SCH) — 3KB
• iova-20240403_lab.xml (EX-101.LAB) — 33KB
• iova-20240403_pre.xml (EX-101.PRE) — 22KB
• tm2410795d1_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. As previously disclosed, on December 11, 2020, a purported stockholder derivative complaint (the "Derivative Action") was filed by plaintiff Leo Shumacher against Iovance Biotherapeutics, Inc. (the "Company"), as nominal defendant, and certain of the Company's current officers and directors, as defendants, in the Court of Chancery in the State of Delaware (the "Court"). On March 12, 2024, the parties agreed to a proposed settlement, set forth in a Stipulation of Compromise and Settlement (the "Stipulation"), which was submitted to the Court for approval. The Stipulation calls for the Company to adopt certain governance changes, the cancellation of certain option awards made to non-employee directors, and for the Company to pay to plaintiff's counsel $600,000 for certain legal fees and expenses. On March 20, 2024, the Court entered a Scheduling Order setting a hearing to determine whether final approval will be given to the settlement. The hearing has been set for July 11, 2024 at 3:15 p.m. in the Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801. As required by the Scheduling Order, the Company is filing the Notice of Pendency of Settlement of Action with this Current Report on Form 8-K, a copy of which is attached hereto as Exhibit 99.1.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Notice of Pendency of Settlement of Action, dated March 25, 2024. 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 3, 2024 IOVANCE BIOTHERAPEUTICS, INC. By: /s/ Frederick G. Vogt Frederick G. Vogt, Interim CEO & General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR